What is the appropriate work‑up and acute management for an adult female with new‑onset migraine presenting with photophobia, bilateral eye pressure, nausea, vomiting, visual disturbances, a normal non‑contrast head CT, and a history of Ehlers‑Danlos syndrome, chronic gum bleeding, prior mold exposure, an NTHFR gene variant, and recent use of CytoQuil and Axia Ease supplements?

Acute Management and Work-Up for New-Onset Migraine with Red Flags

For this patient with new-onset migraine, prominent visual disturbances, bilateral eye pressure, and Ehlers-Danlos syndrome, immediate neuroimaging with MRI brain (with and without contrast) is essential to exclude secondary causes—particularly spontaneous intracranial hypotension and craniocervical instability, which occur with increased frequency in hypermobile connective tissue disorders. 1

Immediate Acute Management

First-Line Pharmacotherapy

Start with NSAIDs as first-line therapy for acute migraine treatment. The most consistent evidence supports ibuprofen (400-800 mg), naproxen sodium (275-550 mg), or aspirin (650-1000 mg) 2. Acetaminophen alone is ineffective for migraine and should not be used 3.

• Given her chronic gum bleeding (likely related to EDS), exercise caution with NSAIDs due to bleeding risk, but they remain the evidence-based first choice
• If NSAIDs are contraindicated due to bleeding concerns, proceed directly to triptan therapy

Second-Line: Triptan Therapy

If NSAIDs fail or are contraindicated, prescribe a triptan immediately 2. Evidence supports:

• Oral sumatriptan, rizatriptan, naratriptan, or zolmitriptan 2
• Given her severe nausea and vomiting, consider non-oral routes: subcutaneous sumatriptan or nasal spray formulations 3

Antiemetic Management

Treat nausea aggressively with antiemetics—nausea itself is disabling and warrants treatment regardless of vomiting 2. Options include:

• Metoclopramide 10 mg IV or oral 3
• Prochlorperazine (Compazine), which also provides headache relief 3

Important caveat: The ED's use of diphenhydramine was suboptimal—it has no evidence for migraine treatment and may have been given for dystonic reaction prophylaxis with antiemetics, but this is not standard practice.

Critical Work-Up for New-Onset Migraine

Neuroimaging Priority

MRI brain with and without contrast is mandatory—not optional—for this presentation because:

1. New-onset migraine in adulthood requires exclusion of secondary causes

2. Ehlers-Danlos syndrome dramatically increases risk of:

   • Spontaneous intracranial hypotension (from dural tears/CSF leaks) 1
   • Craniocervical instability 1
   • Chiari malformation 1
   • Vascular complications including dissection 1

3. Visual disturbances and bilateral eye pressure raise concern for:

   • Increased intracranial pressure
   • Venous sinus thrombosis
   • Posterior circulation pathology

The normal CT scan is insufficient—CT misses most secondary causes of new-onset migraine, particularly intracranial hypotension, Chiari malformation, and early vascular events.

Specialist Referrals

Neurology consultation is appropriate, but neuro-ophthalmology is essential given the prominent visual symptoms and bilateral eye pressure to evaluate for:

• Papilledema (increased intracranial pressure)
• Optic nerve pathology
• Visual field defects

Medication Review and Supplement Concerns

Discontinue CytoQuil and Axia Ease immediately—this recommendation is sound. CytoQuil contains cimetidine, which can cause CNS symptoms including headache, particularly with doses above standard 4. Axia Ease lacks substantive safety data 5.

The MTHFR gene variant is clinically irrelevant to this presentation—it does not cause migraine and should not influence management decisions.

Mold exposure concerns are unsubstantiated—there is no evidence linking mold to new-onset migraine, and this should not distract from appropriate medical evaluation.

Additional Management Considerations

Magnesium Supplementation

Magnesium has fair evidence for migraine prevention but limited acute benefit 2. It's reasonable to trial for prevention but won't address the current attack.

Dysautonomia Screening

Given EDS, assess for orthostatic intolerance and dysautonomia, which frequently interact with headache expression in hypermobile patients 1. Check orthostatic vital signs.

Red Flags Requiring Urgent Attention

• New-onset severe headache in adult
• Visual disturbances
• Connective tissue disorder (EDS)
• Neck pain (could indicate craniocervical pathology)
• Decreased oral intake/dehydration

Common Pitfalls to Avoid

1. Do not rely on normal CT to exclude serious pathology in new-onset migraine
2. Do not dismiss visual symptoms as "typical migraine aura" without imaging
3. Do not overlook EDS-related complications—these patients have fundamentally different risk profiles 1
4. Do not use opioids (meperidine, hydromorphone)—they are ineffective for migraine and risk dependency 3, 6, 7
5. Do not delay MRI for two weeks—this should be expedited given red flags

Optimal Treatment Algorithm

For this specific patient:

1. Immediate: MRI brain with/without contrast (expedite, don't wait 2 weeks)
2. Acute treatment: Trial ibuprofen 600-800 mg with food, OR if bleeding risk too high, start oral triptan (rizatriptan 10 mg or sumatriptan 100 mg)
3. Antiemetic: Add metoclopramide 10 mg or prochlorperazine
4. If oral route fails due to vomiting: Prescribe sumatriptan 6 mg subcutaneous or nasal spray formulation 3
5. Discontinue: CytoQuil and Axia Ease
6. Follow-up: Neurology and neuro-ophthalmology within 1 week (not 2 weeks) with MRI results

The combination of aspirin-acetaminophen-caffeine has strong evidence 8 but may be problematic given her bleeding history—use only if NSAIDs and triptans fail.